» Articles » PMID: 39215342

Integrating the Melanoma 31-gene Expression Profile Test with Clinical and Pathologic Features Can Provide Personalized Precision Estimates for Sentinel Lymph Node Positivity: an Independent Performance Cohort

Overview
Publisher Biomed Central
Date 2024 Aug 30
PMID 39215342
Authors
Affiliations
Soon will be listed here.
Abstract

Introduction: Up to 88% of sentinel lymph node biopsies (SLNBs) are negative. The 31-gene expression profile (31-GEP) test can help identify patients with a low risk of SLN metastasis who can safely forego SLNB. The 31-GEP classifies patients as low (Class 1 A), intermediate (Class 1B/2A), or high risk (Class 2B) for recurrence, metastasis, and SLN positivity. The integrated 31-GEP (i31-GEP) combines the 31-GEP risk score with clinicopathologic features using a neural network algorithm to personalize SLN risk prediction.

Methods: Patients from a single surgical center with 31-GEP results were included (n = 156). An i31-GEP risk prediction < 5% was considered low risk of SLN positivity. Chi-square was used to compare SLN positivity rates between groups.

Results: Patients considered low risk by the i31-GEP had a 0% (0/30) SLN positivity rate compared to a 31.9% (30/94, p < 0.001) positivity rate in those with > 10% risk. Using the i31-GEP to guide SLNB decisions could have significantly reduced the number of unnecessary SLNBs by 19.2% (30/156, p < 0.001) for all patients and 33.0% (30/91, p < 0.001) for T1-T2 tumors. Patients with T1-T2 tumors and an i31-GEP-predicted SLN positivity risk > 10% had a similar SLN positivity rate (33.3%) as patients with T3-T4 tumors (31.3%).

Conclusion: The i31-GEP identified patients with < 5% risk of SLN positivity who could safely forego SLNB. Combining the 31-GEP with clinicopathologic features for a precise risk estimate can help guide risk-aligned patient care decisions for SLNB to reduce the number of unnecessary SLNBs and increase the SLNB positivity yield if the procedure is performed.

Citing Articles

The Prognostic Value of the 31-Gene Expression Profile Test in Cutaneous Melanoma: A Systematic Review and Meta-Analysis.

Durgham R, Nassar S, Gun R, Nguyen S, Asarkar A, Nathan C Cancers (Basel). 2024; 16(21).

PMID: 39518150 PMC: 11545106. DOI: 10.3390/cancers16213714.

References
1.
Vetto J, Hsueh E, Gastman B, Dillon L, Monzon F, Cook R . Guidance of sentinel lymph node biopsy decisions in patients with T1-T2 melanoma using gene expression profiling. Future Oncol. 2019; 15(11):1207-1217. DOI: 10.2217/fon-2018-0912. View

2.
Shannon A, Wood C, Straker 3rd R, Miura J, Ming M, Elenitsas R . Age and Mitogenicity are Important Predictors of Sentinel Lymph Node Metastasis in T1a Melanoma. Ann Surg Oncol. 2021; 28(9):4777-4779. DOI: 10.1245/s10434-021-09929-5. View

3.
Crystal J, Thompson J, Hyngstrom J, Caraco C, Zager J, Jahkola T . Therapeutic Value of Sentinel Lymph Node Biopsy in Patients With Melanoma: A Randomized Clinical Trial. JAMA Surg. 2022; 157(9):835-842. PMC: 9475390. DOI: 10.1001/jamasurg.2022.2055. View

4.
Egger M, Stevenson M, Bhutiani N, Jordan A, Scoggins C, Philips P . Should Sentinel Lymph Node Biopsy Be Performed for All T1b Melanomas in the New 8 Edition American Joint Committee on Cancer Staging System?. J Am Coll Surg. 2019; 228(4):466-472. DOI: 10.1016/j.jamcollsurg.2018.12.030. View

5.
Weitemeyer M, Helvind N, Brinck A, Holmich L, Chakera A . More sentinel lymph node biopsies for thin melanomas after transition to AJCC 8th edition do not increase positivity rate: A Danish population-based study of 7148 patients. J Surg Oncol. 2021; 125(3):498-508. DOI: 10.1002/jso.26723. View